In 2020, CNSA launched its inaugural Corporate Council as a membership program that allows for the Society’s leadership to engage and share insights with representatives of companies developing biologics, pharmaceuticals and medical devices prescribed by clinical neurologists in the treatment of their patients. Eleven companies joined the inaugural Corporate Council.
Now in its third year, the Corporate Council continues to serve in an advisory role to the Society’s leadership by offering the industry perspective on issues impacting clinical care, medical research and patient access.
CNSA wishes to thank and acknowledge all of the companies involved in our Corporate Council program:
- Acadia Pharmaceuticals
- Avanir Pharmaceuticals
- Eli Lilly & Company
- Greenwich Biosciences
- Ionis Pharmaceuticals, Inc
- Neurocrine Biosciences
To learn more about how your company can participate in the
CNSA Corporate Council, please contact:
Michelle Winokur, DrPH
Executive Director, CNSA